Ignite Creation Date:
2024-10-25 @ 7:51 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06547476
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Single Arm Study Investigating the Use of Chidamide and PD-1 Antibody Combination With Anlotinib in HER2-low Unresectable andor Metastatic Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor Tucidinostat chidamide a histone deacetylase inhibitor and anlotinib in advanced breast cancer
Participants must have HER2-low and PD-L1 positive CPS1breast cancer that has been treated before
Participants cancer
Cannot be removed by an operation Has spread to other parts of the body
Participants must have HER2-low and PD-L1 positive CPS1breast cancer that has been treated before
Participants cancer
Cannot be removed by an operation Has spread to other parts of the body
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None